• Something wrong with this record ?

Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide

HC. Gerstein, HM. Colhoun, GR. Dagenais, R. Diaz, M. Lakshmanan, P. Pais, J. Probstfield, MC. Riddle, L. Rydén, D. Xavier, CM. Atisso, A. Avezum, J. Basile, N. Chung, I. Conget, WC. Cushman, E. Franek, N. Hancu, M. Hanefeld, S. Holt, P. Jansky,...

. 2018 ; 20 (1) : 42-49. [pub] 20170714

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18033879

The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. Follow-up will continue until the accrual of 1200 confirmed primary outcomes. Recruitment of 9901 participants (mean age 66 years, 46% women) occurred in 370 sites located in 24 countries over a period of 2 years. The mean duration of diabetes was 10 years, mean baseline HbA1c was 7.3%, and 31% had prior cardiovascular disease. The REWIND trial's international scope, high proportion of women, high proportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle-aged patient seen in general practice throughout the world.

Baker Heart and Diabetes Institute Melbourne Australia

Department of Medicine and Population Health Research Institute McMaster University and Hamilton Health Sciences Hamilton Canada

Department of Medicine Oregon Health and Science University Portland Portland Oregon

Department of Medicine University of Washington Seattle Washington

Dresden Technical University Dresden Germany

ECLA Academic Research Organization and ICR Instituto Cardiovascular de Rosario Rosario Argentina

Eli Lilly and Company Indianapolis Indiana

Endocrinology and Nutrition Department Hospital Clínic i Universitari Barcelona Spain

Hungarian Institute of Cardiology Semmelweis University Budapest Hungary

Instituto Dante Pazzanese de Cardiologia and University Santos Amaro São Paulo Brazil

Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca Romania

Karolinska Institute Stockholm Sweden

Keenan Research Centre in the Li Ka Shing Knowledge Institute of St Michael's Hospital University of Toronto Toronto Canada

Latvijas Universitate Riga Latvia

Medical University of South Carolina Charleston South Carolina

Memphis Veterans Affairs Medical Center Memphis Tennessee

Mossakowski Medical Research Centre Polish Academy of Sciences and Central Clinical Hospital MSW Warsaw Poland

National Research Center for Preventive Medicine Moscow Russia

Research Institute FOSCAL and Medical School Universidad d Santander UDES Bucaramanga Colombia

Robert Koch Medical Center Sofia Bulgaria

St John's Research Institute Bangalore India

Taichung Veterans General Hospital Taichung Taiwan

Universidad de Guadalajara Centro Universitario de Ciencias de la Salud Guadalajara Mexico

Universidad de La Frontera Temuco Chile

Universite Laval Quebec City Canada

University Hospital Motol Prague Czech Republic

University of Cape Town Cape Town South Africa

University of Edinburgh Edinburgh UK

Victoria University of Wellington Wellington New Zealand

Yonsei University Health System Seoul South Korea

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033879
003      
CZ-PrNML
005      
20181026101348.0
007      
ta
008      
181008s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/dom.13028 $2 doi
035    __
$a (PubMed)28573765
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gerstein, Hertzel C $u Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada.
245    10
$a Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide / $c HC. Gerstein, HM. Colhoun, GR. Dagenais, R. Diaz, M. Lakshmanan, P. Pais, J. Probstfield, MC. Riddle, L. Rydén, D. Xavier, CM. Atisso, A. Avezum, J. Basile, N. Chung, I. Conget, WC. Cushman, E. Franek, N. Hancu, M. Hanefeld, S. Holt, P. Jansky, M. Keltai, F. Lanas, LA. Leiter, P. Lopez-Jaramillo, EG. Cardona-Munoz, V. Pirags, N. Pogosova, PJ. Raubenheimer, J. Shaw, WH. Sheu, T. Temelkova-Kurktschiev, . ,
520    9_
$a The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is the first occurrence of the composite of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke. Secondary outcomes include each component of the primary composite cardiovascular outcome, a composite clinical microvascular outcome comprising retinal or renal disease, hospitalization for unstable angina, heart failure requiring hospitalization or an urgent heart failure visit, and all-cause mortality. Follow-up will continue until the accrual of 1200 confirmed primary outcomes. Recruitment of 9901 participants (mean age 66 years, 46% women) occurred in 370 sites located in 24 countries over a period of 2 years. The mean duration of diabetes was 10 years, mean baseline HbA1c was 7.3%, and 31% had prior cardiovascular disease. The REWIND trial's international scope, high proportion of women, high proportion of people without prior cardiovascular disease and inclusion of participants whose mean baseline HbA1c was 7.3% suggests that its cardiovascular and safety findings will be directly relevant to the typical middle-aged patient seen in general practice throughout the world.
650    _2
$a senioři $7 D000368
650    _2
$a kardiovaskulární nemoci $x komplikace $x epidemiologie $x mortalita $x prevence a kontrola $7 D002318
650    _2
$a léky s prodlouženým účinkem $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D003692
650    _2
$a diabetes mellitus 2. typu $x krev $x komplikace $x farmakoterapie $x metabolismus $7 D003924
650    _2
$a diabetické angiopatie $x epidemiologie $x mortalita $x prevence a kontrola $7 D003925
650    _2
$a diabetická kardiomyopatie $x epidemiologie $x mortalita $x prevence a kontrola $7 D058065
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a kombinovaná farmakoterapie $x škodlivé účinky $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a receptor pro glukagonu podobný peptid 1 $x agonisté $x metabolismus $7 D000067757
650    _2
$a glukagonu podobné peptidy $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D004763
650    _2
$a glykovaný hemoglobin $x analýza $7 D006442
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007004
650    _2
$a imunoglobuliny - Fc fragmenty $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D007141
650    _2
$a inkretiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D054795
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mortalita $7 D009026
650    _2
$a multicentrické studie jako téma $7 D015337
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
650    _2
$a rekombinantní fúzní proteiny $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D011993
650    _2
$a výzkumný projekt $7 D012107
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Colhoun, Helen M $u University of Edinburgh, Edinburgh, UK.
700    1_
$a Dagenais, Gilles R $u Universite Laval, Quebec City, Canada.
700    1_
$a Diaz, Rafael $u ECLA Academic Research Organization and ICR Instituto Cardiovascular de Rosario, Rosario, Argentina.
700    1_
$a Lakshmanan, Mark $u Eli Lilly and Company, Indianapolis, Indiana.
700    1_
$a Pais, Prem $u St. John's Research Institute, Bangalore, India.
700    1_
$a Probstfield, Jeffrey $u Department of Medicine, University of Washington, Seattle, Washington.
700    1_
$a Riddle, Matthew C $u Department of Medicine, Oregon Health & Science University Portland, Portland, Oregon.
700    1_
$a Rydén, Lars $u Karolinska Institute, Stockholm, Sweden.
700    1_
$a Xavier, Denis $u St. John's Research Institute, Bangalore, India.
700    1_
$a Atisso, Charles M $u Eli Lilly and Company, Indianapolis, Indiana.
700    1_
$a Avezum, Alvaro $u Instituto Dante Pazzanese de Cardiologia and University Santos Amaro, São Paulo, Brazil.
700    1_
$a Basile, Jan $u Medical University of South Carolina, Charleston, South Carolina.
700    1_
$a Chung, Namsik $u Yonsei University Health System, Seoul, South Korea.
700    1_
$a Conget, Ignacio $u Endocrinology and Nutrition Department, Hospital Clínic i Universitari, Barcelona, Spain.
700    1_
$a Cushman, William C $u Memphis Veterans Affairs Medical Center, Memphis, Tennessee.
700    1_
$a Franek, Edward $u Mossakowski Medical Research Centre, Polish Academy of Sciences and Central Clinical Hospital MSW, Warsaw, Poland.
700    1_
$a Hancu, Nicolae $u Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania.
700    1_
$a Hanefeld, Markolf $u Dresden Technical University, Dresden, Germany.
700    1_
$a Holt, Shaun $u Victoria University of Wellington, Wellington, New Zealand.
700    1_
$a Jansky, Petr $u University Hospital Motol, Prague, Czech Republic.
700    1_
$a Keltai, Matyas $u Hungarian Institute of Cardiology, Semmelweis University, Budapest, Hungary.
700    1_
$a Lanas, Fernando $u Universidad de La Frontera, Temuco, Chile.
700    1_
$a Leiter, Lawrence A $u Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael's Hospital, University of Toronto, Toronto, Canada.
700    1_
$a Lopez-Jaramillo, Patricio $u Research Institute, FOSCAL and Medical School, Universidad d Santander UDES, Bucaramanga, Colombia.
700    1_
$a Cardona-Munoz, Ernesto G $u Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Mexico.
700    1_
$a Pirags, Valdis $u Latvijas Universitate, Riga, Latvia.
700    1_
$a Pogosova, Nana $u National Research Center for Preventive Medicine, Moscow, Russia.
700    1_
$a Raubenheimer, Peter J $u University of Cape Town, Cape Town, South Africa.
700    1_
$a Shaw, Jonathan $u Baker Heart and Diabetes Institute, Melbourne, Australia.
700    1_
$a Sheu, Wayne H-H $u Taichung Veterans General Hospital, Taichung, Taiwan.
700    1_
$a Temelkova-Kurktschiev, Theodora $u Robert Koch Medical Center, Sofia, Bulgaria.
700    1_
$a ,
773    0_
$w MED00005425 $t Diabetes, obesity & metabolism $x 1463-1326 $g Roč. 20, č. 1 (2018), s. 42-49
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28573765 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181026101858 $b ABA008
999    __
$a ok $b bmc $g 1340334 $s 1030873
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 20 $c 1 $d 42-49 $e 20170714 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Archiving options